Effect of Lianhua Qingwen granule combined with cefotaxime sodium on the efficacy and serum inflammatory factors in children with pediatric pneumonia

doi:10.5246/jcps.2023.11.076

Abstract

Abstract:

In the present study, the efficacy of Lianhua Qingwen granule in combination with cefotaxime sodium for the treatment of pediatric pneumonia in children and its impact on serum inflammatory factors were assessed at our hospital involving 86 children of pediatric pneumonia between August 2020 and August 2022. The cases were randomly divided into a study group and a control group, with 43 cases in each. The control group received cefotaxime sodium alone, while the study group received Lianhua Qingwen granule and cefotaxime sodium. This study aimed to compare the overall effectiveness of the two groups by evaluating the levels of TNF-α, hs-CRP, and IL-6 before and after treatment. Additionally, the time taken for body temperature normalization, improvement of wheezing, disappearance of pulmonary rales, and reduction in coughing sputum were assessed in both groups. Finally, the number of adverse reactions was also compared between the two groups. The study found that the total effectiveness of treatment was significantly higher in the study group compared to the control group (P < 0.05). Moreover, the levels of TNF-α, hs-CRP, and IL-6 were significantly lower in the study group than in the control group (P < 0.05). The study group also demonstrated significantly shorter times for body temperature normalization, improvement of wheezing, disappearance of pulmonary rales, and reduction in coughing sputum compared to the control group (P < 0.05). However, the two groups had no significant difference in the number of adverse reactions (P > 0.05). The combination of Lianhua Qingwen granule and cefotaxime sodium exhibited excellent effects in treating pediatric pneumonia. It effectively reduced inflammation, facilitated disease improvement, and demonstrated a high safety profile.

Key words: Lianhua Qingwen, Cefotaxime sodium, Paediatric pneumonia, Serum inflammatory factor

Supporting:

Lei Lu, Chengying Qiu, Qian Chen. Effect of Lianhua Qingwen granule combined with cefotaxime sodium on the efficacy and serum inflammatory factors in children with pediatric pneumonia[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(11): 947-953.

Figures/Tables 4

Table 1. Comparison of clinical effects between the two groups after treatment (n (%)).

Table 2. Comparison of inflammatory mediators between two groups before and after treatment (x ± s).

Table 3. Comparison of symptoms and signs between the two groups after treatment (d, x ± s).

Table 4. Comparison of adverse reactions between two groups during treatment (n (%)).

References 19

[1]	Chen, M.L.; Wang, W.; Xu, L.; Zhu, J.F. Retracted: two new Cd(II) complexes: Luminescent properties and treatment activity on infantile bronchial pneumonia by reducing the over releasing of the inflammatory cytokines. J. Chin. Chem. Soc. 2021, 68, 1654–1662.
[2]	Day, J.W.; Finkel, R.S.; Chiriboga, C.A.; Connolly, A.M.; Crawford, T.O.; Darras, B.T.; Iannaccone, S.T.; Kuntz, N.L.; Peña, L.D.M.; Shieh, P.B.; Smith, E.C.; Kwon, J.M.; Zaidman, C.M.; Schultz, M.; Feltner, D.E.; Tauscher-Wisniewski, S.; Ouyang, H.J.; Chand, D.H.; Sproule, D.M.; Macek, T.A.; Mendell, J.R. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021, 20, 284–293.
[3]	Mselle, M.; Shayo, A.; Mbwasi, R.; Mosha, F.; Pyuza, J.; Mrindoko, P.; Peter, N.; Meleki, E.; Kimambo, E.; Likiliwike, A.; Frisch, L.; Swai, M.; Hatibu, Z.; Iman, A.; Maringo, B.; Kissila, L.; Minga, I.; Mchaile, D. Rare case of surviving infant with strawberry yoghurt like blood diagnosed to be infantile hypertriglyceridemia at 1 month old: a case report. Open J. Pediatr. 2021, 11, 777–785.
[4]	AlShamrani, A.; Alzaid, M.; Fadl, S.; AlFaki, M. A case of infantile exogenous lipoid pneumonia with an unusual complication managed by modified whole lung lavage. Sudan. J. Paediatr. 2021, 82–88.
[5]	Zheng, Y.; Wang, Y.Y.; Zhu, X.L.; Diao, Y.Q.; Chen, Y.Q.; Chen, G. Circ_0038467 regulates lipopolysaccharide-mediated cell proliferation, apoptosis, and inflammatory response by miR-195-5p/TLR4 axis through NF-κB pathway in MRC-5 cells. Biosci. Biotechnol. Biochem. 2021, 85, 1639–1649.
[6]	Lu, Z.J.; Wu, L.Y.; Mou, Y.Y.; Duan, H.M.; Chen, R.C.; Xiao, Y.; Zheng, W.J. Meta analysis and systematic review of the efficacy and safety of Lianhua Qingwen as an adjuvant therapy for adult pneumonia. Chin. J. Tradit. Chin. Med. 2021, 46, 48–59.
[7]	Zhu, F.T. Practical Pediatrics. 9th Edition. Beijing: People’s Health Publishing House. 2022.
[8]	Lv, W.G.; Zhang, Y.; Song, G.H.; Guan, Z.W.; Yu, S.P.; Guo, Y.R.; Chen, X.S.; Zhang, G.H.; Yang, X.Q.; Sun, M.M.; Zhang, B.X.; Han, Y.X. Qianjin Weigan decoction modified formula combined with azithromycin in the treatment of mycoplasma pneumonia in children with phlegm heat stagnation and blood stasis syndrome. Chin. J. Integr. Tradit. Chin. West. Med. 2021, 41, 15–18.
[9]	Biswas, D.; Dhindsa, J.; Strickland, L.; Pucci, L.; ElMallah, M. Phrenic and Hypoglossal motor unit pathology in a Spinocerebellar ataxia type 7 mouse model. FASEB J. 2021, 35, 270–277.
[10]	Wang, L.L.; Niu, L.J.; Zhang, L.; Xia, L.; Zhao, Y.N.; DouM, Y.X. The correlation between serum IL-25, IL-33, eosinophil chemokines, and lung function in children with Mycoplasma pneumoniae pneumonia. Chin. J. Hosp. Infect. 2022, 87, 540–544.
[11]	Zhu, R.R.; Zhang, M.M. Observation on the efficacy of multi-sensory stimulation therapy in the treatment of delayed language development in children. Contemp. Med. Thesis. 2021, 37, 299–302.
[12]	Chen, J.N.; Lin, Q.Y.; Feng, N.C.; Chen, S.Q.; Wang, P.; Sun, X.L. The relationship between the expression of CD162, CXCR2, and CXCR4 on neutrophils and Mycoplasma pneumoniae infection in children. Chin. J. Hosp. Infect. 2022, 32, 1397–1400.
[13]	Zhao, W.H. Laboratory testing of Mycoplasma pneumoniae and clinical efficacy study of integrated traditional Chinese and Western medicine in the treatment of pediatric Mycoplasma pneumoniae pneumonia. Mod. Digest. Int. Diagn. Treatment. 2022, 22, 731–736.
[14]	Lin, Q.; Miao, C.X.; Wei, X.H.; Chen, S.Y.; Qian, H.J. Lianhua Qingwen granule combined with azithromycin sequential treatment for children with mycoplasma pneumoniae pneumonia complicated with atelectasis and its effect on T lymphocyte subsets and inflammatory factors. J. Mod. Integr. Tradit. Chin. West. Med. 2019, 28, 153–158.
[15]	Zhu, C.L.; Hu, F.Y. Literature analysis of Lianhua Qingwen for viral infectious diseases. J. Yichun Univ. 2020, 10, 425–433.
[16]	Li, H.; Zhou, D.M.; Chen, L.; Tian, W.N. Practice and thinking of prevention and control nursing management combined with Lianhua Qingwen capsule in the treatment of COVID-19 under the regional medical consortium model. J. Shenyang Pharm. Univ. 2021, 38, 6–7.
[17]	Sun, J.Y.; Liu, Q.Y.; Wen, X.F.; Wang, X.Y.; Zhang, L.; Zhang, T.C.; Sun, S.J.; Shang, J.H.; Chen, C.L. The effect of desloratadine combined with Lianhua Qingwen on children with allergic rhinitis, serum inflammatory factors, adhesion factors, and quality of life. Hebei Med. J. 2022, 44, 1334–1337, 1341.
[18]	Yin, X.; Jiang, D.F.; Liu, X. Lianhua Qingwen granule combined with recombinant human interferon α-observation on the therapeutic effect of 2b injection on pediatric herpetic angina. J. Clin. Exp. Med. 2022, 21, 1426–1430.
[19]	Ye, F.; Huang, B.Y.; Zhao, L.; Lu, R.J.; Deng, Y.; Wang, W.; Ren, J.; A, R.H.; Wang, W.L.; Tan, W.J. In vitro anti novel coronavirus activity and cytotoxicity of eight traditional Chinese medicines including Lianhua Qingwen Granule. J. Virol. 2022, 38, 284–289.